Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib plus paclitaxel versus placebo plus paclitaxel in second-line advanced gastric or gastro-oesophageal junction cancer
2015-001605-14Phase 2Terminated
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in gastric cancer (GC) and esophagogastric junction cancer comparing Lynparza + paclitaxel with Placebo + paclitaxel (2 arms). Primary endpoint: Overall survival. Started Jul 2015; status: terminated.
02
Drugs
olaparibpaclitaxel
03
Conditions
gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on 2015-001605-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001605-14.